Thursday - July 09, 2026

Category Archives: Science

Epilepsy Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Epilepsy Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline … Continue reading →

Food Allergy Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Food Allergy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Food Allergy pipeline landscape. It covers the Food Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Major Depressive Disorder Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Major Depressive Disorder Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Non-Alcoholic Fatty Liver Disease Pipeline Accelerates as 90+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical … Continue reading →

Marginal Zone Lymphoma Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Marginal Zone Lymphoma Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Neuroblastoma Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Neuroblastoma Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Neuroblastoma pipeline landscape. It covers the Neuroblastoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroblastoma Pipeline … Continue reading →

Sjögren’s Disease Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Sjogren’s Syndrome Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Sjogren’s Syndrome pipeline landscape. It covers the Sjogren’s Syndrome pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

HER2 Positive Breast Cancer Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading →

Chronic Refractory Gout (CRG) Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Novel Urate-Lowering Therapies and Rising Burden of Uncontrolled Gout | DelveInsight

The Chronic Refractory Gout (CRG) Market is growing due to the rising prevalence of chronic gout, uncontrolled hyperuricemia, and increasing demand for effective urate-lowering therapies. Growing awareness of treatment-resistant gout and the development of pipeline candidates such as NASP (SEL-212), … Continue reading →

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market is Projected to Witness Robust Growth by 2036 Owing to the Launch of First-in-Class Disease-Modifying Therapies and Expanding Bronchiectasis Treatment

The Non-Cystic Fibrosis Bronchiectasis (NCFB) Market is growing due to the rising prevalence of chronic respiratory diseases, improved diagnosis through HRCT, increasing healthcare expenditure, and advancements in targeted therapies. The approval of BRINSUPRI (brensocatib) and promising pipeline candidates such as … Continue reading →